Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Plast Reconstr Surg ; 145(1): 42e-50e, 2020 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-31881603

RESUMO

BACKGROUND: With an increase in recent years in the number of people receiving cosmetic facial injection treatments of hyaluronic acid, the incidence of hyaluronic acid embolism has also increased commensurately. Hyaluronic acid embolism leads to serious complications, including blindness, eye and eyelid movement disorders, skin necrosis, and cerebral embolism. However, there is a lack of robust clinical evidence regarding the benefits of treatment for hyaluronic acid embolism by intraarterial thrombolysis therapy. METHODS: This study included 24 patients with a decrease in visual acuity and other complications induced by facial hyaluronic acid injection. Patients underwent emergency intraarterial thrombolysis therapy by injection of hyaluronidase (500 to 1500 units) alone or hyaluronidase (750 to 1500 units) combined with urokinase (100,000 to 250,000 units), followed in both cases by a general symptomatic treatment and nutritional therapy. RESULTS: Ten (42 percent) of 24 patients ultimately had improvements to visual acuity, even when the clinical application of the thrombolytic treatments had passed the recommended window for optimal treatment. In all cases, patients' facial skin necrosis was restored to nearly normal appearance. In addition, the authors found that hyaluronidase combined with urokinase was a more effective therapy than hyaluronidase alone. CONCLUSIONS: The authors' results indicate that intraarterial thrombolysis therapy is beneficial to patients suffering from blindness induced by hyaluronic acid embolism. The therapy was shown to be worthy of clinical application because it alleviated the impairment to patients' vision and was also beneficial in the recovery from other serious complications, including eye movement disorder, eye edema, headaches, and skin necrosis. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.

2.
Plast Reconstr Surg ; 2019 Sep 30.
Artigo em Inglês | MEDLINE | ID: mdl-31577662

RESUMO

BACKGROUND: With an increase in recent years in the number of people receiving cosmetic facial injection treatments of hyaluronic acid (HA), the incidence of HA embolism has also commensurately increased. HA embolism leads to serious complications including blindness, eye and eyelid movement disorders, skin necrosis and cerebral embolism. However, there is a lack of robust clinical evidence regarding the benefits of treatment for HA embolism by Intra-arterial thrombolysis (IAT) therapy. METHODS: In this study, we included 24 patients with a decrease in visual acuity and other complications induced by facial HA injection. These patients underwent emergency IAT therapy by injection of hyaluronidase (500-1,500 units) alone or hyaluronidase (750-1,500 units) combined with urokinase (100,000-250,000 units), followed in both cases by a general symptomatic treatment and nutritional therapy. RESULTS: In the 24 patients, 10 patients (42%) ultimately had improvements to visual acuity, even in cases when the clinical application of the thrombolytic treatments had passed the recommended window for optimal treatment. In all cases the patients' facial skin necrosis was restored to nearly normal appearance. In addition, we found that hyaluronidase combined with urokinase was a more effective therapy than hyaluronidase alone. CONCLUSION: Our results indicate that IAT therapy is beneficial to patients suffering from blindness induced by HA embolism. IAT therapy was shown to be worthy of clinical application because it alleviated the impairment to patients' vision , and was also beneficial in the recovery from other serious complications including eye movement disorder, eye edema, headaches, and skin necrosis.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA